Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients

Objectives The primary objective was to evaluate long-term treatment persistence and safety of natalizumab in Finnish multiple sclerosis patients. The secondary objectives were to assess patient characteristics, use of natalizumab-related safety protocol, and treatment persistence in patients with d...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis journal - experimental, translational and clinical translational and clinical, 2023-10, Vol.9 (4), p.20552173231204466-20552173231204466
Main Authors: Verkkoniemi-Ahola, Auli, Hartikainen, Päivi, Hassi, Katja, Kuusisto, Hanna, Lahdenperä, Sanni, Mehtälä, Juha, Viitala, Matias, Ylisaukko-oja, Tero, Soilu-Hänninen, Merja
Format: Article
Language:English
Subjects:
Clinical decision making
Multiple sclerosis
Original
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives The primary objective was to evaluate long-term treatment persistence and safety of natalizumab in Finnish multiple sclerosis patients. The secondary objectives were to assess patient characteristics, use of natalizumab-related safety protocol, and treatment persistence in patients with different anti-John Cunningham virus antibody statuses (John Cunningham virus status). Materials & Methods All adult multiple sclerosis patients in the Finnish multiple sclerosis register who started natalizumab between 1/2006 and 12/2018 were included in this study and followed retrospectively until treatment discontinuation or end of follow-up (12/2019). Results In total, 850 patients were included. Median duration of natalizumab treatment was 7.8 years in John Cunningham virus negative (n = 229) and 2.1 years in John Cunningham virus positive patients (n = 115; p 
ISSN:2055-2173
2055-2173
DOI:10.1177/20552173231204466